Maze Therapeutics, Inc. (MAZE)
| Market Cap | 499.93M |
| Revenue (ttm) | 167.50M |
| Net Income (ttm) | -18.27M |
| Shares Out | 43.78M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,507 |
| Open | 11.27 |
| Previous Close | 11.27 |
| Day's Range | 10.93 - 11.64 |
| 52-Week Range | 9.88 - 17.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.67 (+124.78%) |
| Earnings Date | n/a |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidn... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price forecast is $25.67, which is an increase of 124.78% from the latest price.
News
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop nove...
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech lis...
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop nove...
Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
Maze Therapeutics Seeks IPO For Trials Ramp-Up
Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidne...
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO) filing on Tuesday.
Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public.
Maze Therapeutics IPO Registration Document (S-1)
Maze Therapeutics has filed to go public with an IPO on the NASDAQ.